GlycoMimetics Says FDA Clears Addition Of Time-Based Final Analysis To Pivotal Phase 3 Study Of Uproleselan In Relapsed/Refractory Acute Myeloid Leukemia
Portfolio Pulse from Benzinga Newsdesk
GlycoMimetics announced that the FDA has cleared the addition of a time-based final analysis to the pivotal Phase 3 study of Uproleselan in relapsed/refractory acute myeloid leukemia. The final analysis will be conducted after the earlier of 295 survival events or the FDA-aligned cutoff date, with topline results expected by the end of Q2 2024.
June 15, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GlycoMimetics' stock may be positively impacted by the FDA's clearance of a time-based final analysis for the Phase 3 study of Uproleselan in acute myeloid leukemia.
The FDA's clearance of the time-based final analysis for GlycoMimetics' Phase 3 study of Uproleselan is a positive development for the company. This may lead to increased investor confidence in the company's progress and potential for future success, which could positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100